IDH3A and glioblastoma: We eventually started Depatux-M treatment in 9 patients with advanced high-grade gliomas (7 isocitrate dehydrogenase [IDH]1-wildtype glioblastoma, 1 IDH1-mutated glioblastoma, and 1 IDH1-wildtype anaplastic astrocytoma), median age 60 years, (range 29–71 years), and Karnofsky performance score 90% (n = 3), 80% (n = 2), 70% (n = 2), and 60–50% (n = 2).